Equities Analysts Issue Forecasts for ELEV Q3 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Elevation Oncology in a note issued to investors on Tuesday, June 10th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.11) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share.

Elevation Oncology (NASDAQ:ELEV) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04).

Other analysts also recently issued research reports about the company. Wedbush downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 20th. Leerink Partnrs downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 20th. TD Cowen downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a research note on Monday. Piper Sandler downgraded Elevation Oncology from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $10.00 to $0.70 in a research note on Friday, March 21st. Finally, Citigroup downgraded Elevation Oncology to a “market perform” rating in a research note on Friday, March 21st. Eleven analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.39.

Elevation Oncology Trading Down 0.8%

Shares of NASDAQ:ELEV opened at $0.38 on Wednesday. The business’s 50-day moving average is $0.33 and its 200 day moving average is $0.49. Elevation Oncology has a 1 year low of $0.22 and a 1 year high of $3.56. The firm has a market capitalization of $22.48 million, a P/E ratio of -0.46 and a beta of 1.43. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77.

Hedge Funds Weigh In On Elevation Oncology

A number of hedge funds have recently bought and sold shares of ELEV. BML Capital Management LLC purchased a new position in Elevation Oncology during the first quarter worth approximately $1,526,000. Allostery Investments LP acquired a new position in shares of Elevation Oncology during the fourth quarter valued at approximately $243,000. Palumbo Wealth Management LLC raised its holdings in shares of Elevation Oncology by 302.3% during the first quarter. Palumbo Wealth Management LLC now owns 278,002 shares of the company’s stock valued at $72,000 after acquiring an additional 208,897 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of Elevation Oncology during the fourth quarter valued at approximately $113,000. Finally, Nuveen LLC acquired a new position in shares of Elevation Oncology during the first quarter valued at approximately $45,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.